Dallas, TX - The Publisher of Daily OTC Stocks Newsletter (http://www.otcpicks.com/hotpicks.htm) and Free Red Hot Stock Picks presents the following penny stocks to watch today: El Maniel International Inc. (OTCBB: EMLL), Tao Minerals Ltd. (OTC: TAON), Dynegy Inc. (NYSE: DYN) and Trubion Pharmaceuticals Inc. (Nasdaq: TRBN).
EL MANIEL INTERNATIONAL INCORPORATED (OTC: EMLL) "Up 144.44% on Friday"
El Maniel International, Inc. intends to manufacture and distribute cigars under the PLC brand name in the United States. The company was founded in 2007 and is based in Raleigh, North Carolina. As of March 10, 2010, El Maniel International, Inc. operates as a subsidiary of Co-Max International Ltd.
TAO MINERALS LIMITED (OTCBB: TAON) "Up 60.00% on Friday"
Tao Minerals Ltd. is a mining exploration and development company formed to acquire, develop, and exploit natural resource properties focusing primarily on the rich, yet highly underdeveloped gold deposits of Colombia doing so in a socially and environmentally responsible manner.
DYNERGY INCORPORATED (NYSE: DYN) "Up 62.95% on Friday"
Through its subsidiaries, Dynegy Inc. produces and sells electric energy, capacity and ancillary services in key U.S. markets. The power generation portfolio consists of approximately 12,200 megawatts of baseload, intermediate and peaking power plants fueled by a mix of natural gas, coal and fuel oil.
TRUBION PHARMACEUTICALS INCORPORATED (NASDAQ: TRBN) "Up 50.00% on Friday"
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Pfizer collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the Company's Facet collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules as well as simultaneously neutralizing soluble ligands.
The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily penny stock alerts go to http://www.otcpicks.com/hotpicks.htm
Get the latest updates via Twitter at www.twitter.com/otcpicks or through Facebook - www.facebook.com/otcpicks.
Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.
